Novel Biotechnology develops plasmid DNA production solutions through its NBx platform, aiming to deliver productivity, speed, and quality for plasmid manufacturing. The company has developed a proprietary strain, demonstrated proof of concept with multiple plasmid constructs, and generated meaningful revenue through its services business. Over recent months it has tested complex plasmid constructs and begun scaling up its proprietary platform with external partners. Novel plans a commercial launch of NBx for plasmid manufacturing in Q4 2023. In the interim it will continue to use established platforms to produce R&D and pre-clinical plasmid material for existing industrial and academic clients. The company intends to use new funds to expand its plasmid services business and expedite platform R&D initiatives.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2023